심장판막 기기 시장 : 판막 위치별, 제품 유형별, 시술 방법별, 연령층별, 최종 사용자별, 유통 채널별 예측(2026-2032년)

The Heart Valve Devices Market is projected to grow by USD 26.89 billion at a CAGR of 10.39% by 2032.

Heart valve devices are central to the treatment of aortic, mitral, tricuspid, and pulmonary valve disease, spanning mechanical valves, bioprosthetic valves, annuloplasty systems, transcatheter aortic valve replacement (TAVR) platforms, transcatheter mitral repair and replacement technologies, and emerging tricuspid solutions.

Demand is supported by well-documented demographic and clinical drivers: population aging, the high prevalence of calcific aortic stenosis in older adults, persistent rheumatic heart disease burden in many low- and middle-income countries, and growing use of minimally invasive structural heart procedures. Hospitals, cardiac centers, and ambulatory cardiovascular programs are prioritizing heart valve devices that improve survival, reduce recovery time, and support durable outcomes under increasingly value-based reimbursement models.

Transformative Shifts in the Heart Valve Devices Landscape

The heart valve devices landscape is shifting from open surgical valve replacement toward catheter-based and hybrid structural heart interventions. TAVR has moved from inoperable and high-risk patients into broader risk categories in major markets, supported by randomized clinical evidence and guideline adoption. This has accelerated investment in delivery systems, imaging compatibility, valve durability, and treatment planning workflows.

Another transformative shift is the expansion beyond aortic valve disease. Mitral and tricuspid valve therapies are gaining clinical and commercial attention because these conditions are common in older and heart failure populations, yet historically undertreated. Device development is increasingly focused on precision delivery, reduced paravalvular leak, lower pacemaker rates, retrievability, and long-term hemodynamic performance.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence the full heart valve device lifecycle, from diagnosis and patient selection to procedural planning and post-market surveillance. AI-enabled echocardiography, CT segmentation, and automated measurement tools can support more consistent assessment of annular dimensions, calcification, left ventricular function, and procedural risk.

The cumulative impact is operational as well as clinical. AI can improve cath lab scheduling, inventory planning, and real-world evidence generation by analyzing registry data, imaging archives, and electronic health records. However, adoption depends on validated algorithms, transparent regulatory pathways, cybersecurity controls, and clinician oversight to ensure that AI augments, rather than replaces, expert structural heart decision-making.

Key Regional Insights

Asia-Pacific is a high-opportunity region as China, India, Japan, South Korea, and Australia expand structural heart programs, while large elderly populations and improving access to tertiary cardiac care increase demand for both surgical and transcatheter heart valve devices. Japan and Australia benefit from mature reimbursement systems and advanced hospital infrastructure, while China and India combine large patient pools with rising domestic manufacturing capabilities, improving diagnostic access, and public-private investment in cardiac care.

North America remains a leading innovation and adoption hub due to high structural heart procedure volumes, sophisticated imaging infrastructure, strong clinical trial activity, and established reimbursement for approved TAVR and selected transcatheter valve procedures. Europe shows broad clinical expertise and guideline-driven adoption, with the European Union emphasizing medical device regulation, evidence generation, unique device identification, and post-market performance monitoring for cardiovascular implants.

Latin America, the Middle East, and Africa present mixed but important adoption conditions. Brazil and Mexico anchor Latin American demand through large urban cardiology networks and public-private treatment pathways, while GCC countries in the Middle East invest in specialist cardiac centers, advanced imaging, and medical tourism. In Africa, rheumatic heart disease continues to drive valve disease burden, particularly among younger populations, but access is constrained by specialist availability, affordability, uneven surgical capacity, and limited structural heart infrastructure.

Key Group Insights

Within ASEAN, expanding urban hospital networks and rising cardiovascular disease awareness are supporting gradual uptake of heart valve devices, especially in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. Access remains uneven across the region, making reimbursement design, physician training, referral pathways, and regional centers of excellence critical for wider adoption of surgical valves, TAVR, and emerging mitral and tricuspid interventions.

The GCC is characterized by high healthcare investment, growing structural heart capabilities, and demand for premium minimally invasive cardiovascular technologies. The European Union is shaped by rigorous clinical evidence expectations under the Medical Device Regulation, while BRICS countries combine large unmet need with cost-sensitive procurement, expanding tertiary hospital capacity, and growing domestic production capacity for cardiovascular devices.

G7 markets lead in innovation, clinical trial density, advanced imaging, registry participation, and early adoption of next-generation transcatheter valve devices. NATO countries overlap significantly with high-income cardiovascular markets, where procurement resilience, supply chain security, cybersecurity readiness, and clinical standardization are increasingly important to hospital systems, payers, and device manufacturers.

Key Country Insights

The United States is the largest commercial and clinical innovation market for heart valve devices, supported by FDA-authorized technologies, large registry infrastructure, high TAVR penetration, and extensive structural heart programs. Canada follows evidence-based adoption through provincial health systems, while Mexico is expanding access through private hospitals and major urban cardiac centers. Brazil is Latin America's key market, with demand shaped by public-private care pathways, advanced cardiology hubs, and the continued need to address both degenerative and rheumatic valve disease.

In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain strong procedure capabilities and established cardiothoracic and interventional cardiology expertise, with Germany historically recognized for high structural heart procedure volumes. Russia has demand from aging populations and cardiovascular disease burden, although access to advanced technologies can be affected by procurement complexity, reimbursement variation, and geopolitical constraints.

China and India represent large long-term opportunities due to population scale, aging demographics, rising diagnosis of valvular heart disease, and expanding cardiac infrastructure. Japan and South Korea are advanced technology markets with strong physician expertise, high-quality hospital systems, and structured adoption of minimally invasive valve procedures, while Australia combines high clinical standards, reimbursement discipline, registry-based evaluation, and systematic adoption of approved heart valve technologies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated clinical evidence, including long-term durability, quality-of-life outcomes, reduced rehospitalization, stroke and pacemaker outcomes, and device performance in anatomically complex patients. Evidence strategies should include randomized trials where feasible, real-world registries, health-economic analyses, and post-market surveillance aligned with regulatory expectations for implantable cardiovascular devices.

Manufacturers should also invest in physician education, imaging-based planning tools, proctoring programs, and center-of-excellence partnerships to improve outcomes and accelerate appropriate adoption. Commercial strategies should balance premium innovation in mature markets with affordability, local partnerships, training infrastructure, and service support in emerging markets where diagnosis and treatment access gaps remain substantial.

Research Methodology

This executive summary is based on structured secondary research, including peer-reviewed cardiology literature, major society guidelines, public regulatory documents, clinical trial registries, hospital adoption trends, and epidemiological sources covering valvular heart disease and cardiovascular care.

The analysis applies cross-validation across clinical, regulatory, demographic, and commercial indicators. Regional, group, and country insights were assessed through healthcare infrastructure, reimbursement maturity, disease burden, procedure adoption, availability of specialist structural heart programs, regulatory readiness, and access to advanced cardiac imaging.

Conclusion

Heart valve devices are positioned for continued advancement as aging populations, underdiagnosed valve disease, and clinical preference for minimally invasive intervention reshape cardiovascular care. TAVR remains the benchmark for transformation, while mitral and tricuspid innovation is opening the next phase of structural heart development.

Organizations that combine robust clinical evidence, AI-enabled workflow support, physician training, resilient supply chains, and market-specific access strategies will be best positioned to improve adoption while strengthening patient outcomes across mature and emerging healthcare systems.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Heart Valve Devices Market, by Valve Position

• 7.1. Aortic Valve
• 7.2. Mitral Valve
• 7.3. Pulmonary Valve
• 7.4. Tricuspid Valve

8. Heart Valve Devices Market, by Product Type

• 8.1. Mechanical Heart Valves
  • 8.1.1. Bileaflet
  • 8.1.2. Tilting Disc
  • 8.1.3. Caged Ball
• 8.2. Biological Heart Valves
  • 8.2.1. Xenograft
  • 8.2.2. Homograft

9. Heart Valve Devices Market, by Procedure Type

• 9.1. Transcatheter Valve Interventions
• 9.2. Open-Heart Surgery
• 9.3. Minimally Invasive Surgery

10. Heart Valve Devices Market, by Age Group

• 10.1. Adult
• 10.2. Pediatric
• 10.3. Geriatric

11. Heart Valve Devices Market, by End User

• 11.1. Ambulatory Surgical Centers
• 11.2. Hospitals
• 11.3. Specialty Cardiology Clinics
• 11.4. Research & Academic Centers

12. Heart Valve Devices Market, by Distribution Channel

• 12.1. Online
• 12.2. Offline

13. Heart Valve Devices Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Heart Valve Devices Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Heart Valve Devices Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Edwards Lifesciences Corporation
• 17.2. Medtronic plc
• 17.3. Abbott Laboratories
• 17.4. Boston Scientific Corporation
• 17.5. Corcym S.r.l.
• 17.6. Artivion, Inc
• 17.7. Peijia Medical Limited
• 17.8. Meril Life Sciences Pvt. Ltd.
• 17.9. Venus Medtech (Hangzhou) Inc.
• 17.10. Lepu (Beijing) Medical Devices Co., Ltd.
• 17.11. Biosensors International Group, Ltd.
• 17.12. MicroPort Scientific Corporation
• 17.13. JenaValve Technology, Inc.
• 17.14. 4C Medical Technologies, Inc.
• 17.15. Anteris Technologies Global Corp.
• 17.16. Braile Biomedica
• 17.17. Colibri Heart Valve LLC
• 17.18. Foldax, Inc.
• 17.19. HighLife Medical
• 17.20. Sahajanand Medical Technologies Limited
• 17.21. TTK Healthcare Limited
• 17.22. W. L. Gore & Associates, Inc.
• 17.23. Xeltis B.V.